February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies CME Congresses . February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial CME Congresses . February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma CME Congresses . February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies CME Congresses . January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter? CME Congresses . January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter? January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm CME Congresses . January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm January 19th- Luspatercept in Lower-Risk MDS- where do we stand CME Congresses . January 19th- Luspatercept in Lower-Risk MDS- where do we stand January 12th- “Genomically Smoldering” Myeloma Really Smoldering? CME Congresses . January 12th- “Genomically Smoldering” Myeloma Really Smoldering? January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance CME Congresses . January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation CME Congresses . December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24 Page25 Page26 Page27
